Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
ERIS Lifesciences Ltd

| Q3 FY26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤20th Feb 26

Summary : Eris Lifesciences reported strong Q3/9M growth, driven by significant market share gains in Insulin and robust international business, with key new product launches like Semaglutide and Esaxerenone poised for future expansion.

Management Perspective positive : Management expressed being 'happy to share' strong visibility, 'excited about the upcoming launch' of GLP-1 and Esaxerenone, and confident in achieving market share targets and international business aspirations. They highlighted 'highest ever quarter' revenue and 'substantial growth' projections.

Concall Report Analysis & Insights

Business Overview

  1. Domestic Branded Formulations (DBF) revenue grew 10% YoY in Q3 and 9M FY26.
  2. Consolidated Q3 revenue reached INR 807 crores, an 11% YoY growth.
  3. International business revenue grew 45% in Q3 to INR 111 crores.
  4. Profit after Tax (PAT) from continuing operations increased by nearly 40% in Q3.
  5. EBITDA margin for 9M FY26 improved by 70 basis points to 36%.

Future Growth Prospects

  1. Visibility for 12% DBF revenue growth in FY26 with 37% operating margin.
  2. Achieved 26% market share in RHI cartridges, targeting 25% in overall RHI plus Glargine.
  3. Upcoming launch of Insulin Analogs (Aspart, Degludec) and Esaxerenone for hypertension.
  4. Semaglutide launch imminent following CDSCO approval, expected to be a significant market.
  5. International business projected to reach INR 550-600 crores revenue in FY27, driven by CDMO.

Management Insights

  1. Discontinuing non-core tail-end brands to improve operating profit and margins.
  2. Front-loading capital investment for Injectables, Insulin, and GLP-1 due to strategic opportunities.
  3. Esaxerenone is a disease-modifying drug for hypertension with kidney benefits, a game-changer.
  4. Semaglutide is a very big opportunity, focusing on diabetes and metabolic issues in India.
  5. Net debt to EBITDA ratio is expected to reach 1.5x by the end of the calendar year.

Signs of Skepticism

  1. Analyst questioned the reason for low cash flow conversion in Q3 compared to previous year.
  2. Analyst inquired about the softness in gross margin for the quarter and year-to-date.
  3. Analyst asked about the R&D spend not being separately reported for FY26.
  4. Analyst questioned if the INR 1,000 crore CDMO order book would continue growing and its execution timeline.

Risk Factors

  1. Discontinuation of non-core brands will impact DBF revenue by 2% next year.
  2. OAD portfolio growth is currently lagging market due to FDC bans, expected to stabilize in 2-3 quarters.
  3. Initial gross margins for Semaglutide will be lower, but overall impact on company margins is minimal.
  4. Cash flow conversion was low in Q3, expected to improve by reducing debtor days.

Good To Know

  1. CapEx guidance for the next 3 years remains INR 200-250 crore per annum.
  2. One-time adjustment of INR 17 crore was taken as an exceptional item due to new labor code.
  3. R&D expenses, significant in OpEx, will be reported separately from next year.
  4. The company has an exclusive partnership with Natco for Semaglutide supply.
  5. Insulin manufacturing at Bhopal is on course, with vials internalized and cartridges starting Q2 next financial year.

Key Drivers

  1. Semaglutide launch will drive growth.
  2. Insulin market share gains continue.
  3. International business shows strong growth.
  4. New product Esaxerenone launched.

Key Analyst Discussions

Competitive Environment

  1. Eris has gained significant market share in Insulin, tripling it in less than 2 years.
  2. Expects to share insulin market with Lupin, with a 60:27-65:27 split.
  3. Innovator's relevant SKU in insulin market is tapering off to 15-20%.

Market Trends & Consumer Behavior

  1. Semaglutide market in India will focus on diabetes, fatty liver, PCOD, and sleep apnea, not just obesity.
  2. Indian population is 'thin fat,' targeting 10-12% weight loss, not morbid obesity.
  3. Cardiovascular benefits of Semaglutide are highly encouraging for the Indian market.

Financial Highlights

  1. Debt repayment schedule delay is due to front-loading CapEx for strategic opportunities.
  2. Low cash flow conversion in Q3 is attributed to product mix and recent acquisitions in injectables/hospital supplies.
  3. Gross margin softness is due to product mix, expected to reverse with insulin production shift.
  4. Operational cost drag from manufacturing initiatives is INR 60-90 crore annually, expected to break even next year.

Product Composition

  1. Semaglutide will initially have lower gross margins but will not materially impact overall DBF margins.
  2. Insulin manufacturing at Bhopal will provide a significant production boost and improve margins.
  3. Discontinuing low-EBITDA, non-core brands to improve overall profitability and focus on strength areas.

Strategic Considerations

  1. GLP-1 launch strategy involves leveraging existing metabolic teams, not immediately adding new field force.
  2. The partnership with Natco for Semaglutide supply is exclusive at some level.
  3. Evaluating Semaglutide CDMO opportunity for both domestic and export markets.
  4. Swiss and Ahmedabad facilities have sufficient capacity for CDMO expansion, with Unit 3 commissioning in FY28.
ERIS Lifesciences Ltd (ERIS) Concall Report Analysis & Insights | Dhanarthi